J&J Topamax “approvable” for migraines
Executive Summary
Johnson & Johnson plans to respond around year-end to an Oct. 23 "approvable" letter for Topamax (topiramate) for the supplemental indication of prophylaxis of migraine headache. Final approval awaits additional analysis of safety data and labeling negotiations...